

PARADIGM BIOPHARMACEUTICALS LIMITED



ASX RELEASE

3rd June 2020

Paradigm adds two members to Senior Management team

Paradigm Biopharmaceuticals Ltd (ASX: PAR) Paradigm is pleased to announce the recent appointments of Jeannie Joughlin and Michael Imperiale to the team. Dr Joughlin and Dr Imperiale add significant clinical and commercial development experience while continuing to strengthen the Paradigm team as we prepare for Phase 3 trials in both Osteoarthritis (OA) and Mucopolysaccharidosis (MPS).

Chief Operating Officer, Dr Jeannie Joughlin, joined the Paradigm team in June 2020. During almost 9 years in the US she held senior executive roles with Enable Injections and CSL Behring. Upon her return to Australia early 2019, Jeannie provided ongoing leadership support to Enable Injections, joined an ASX-listed company as Non-Executive Director and provided guidance as a principal commercial advisor to Australian biotechnology and medical technology companies.

Jeannie is an experienced biopharmaceutical and medical device leader with over 20 years' experience in global biopharmaceutical companies and start-up environments. Her responsibilities and experience have included extensive post-doctoral research, clinical trial management, brand management, licensing and business development, team leadership, strategic planning, capital raising, as well as partner relationship/alliance management. Jeannie holds a Bachelor of Science (Hons) and a Doctor of Philosophy (Immunology).

While at CSL Behring, Jeannie was responsible for/involved with the in-licensing of Tramadol from Grunenthal into the Australian market.

Global Head of Safety, Dr. Michael Imperiale joins Paradigm Biopharmaceuticals with more than 25 years of international drug development experience in the biotechnology and pharmaceutical industry.

Previously, Dr. Michael Imperiale worked at Nektar Therapeutics, where he led the development of their Immuno-Oncology and Pain programs. Prior to joining Nektar, Dr. Imperiale was the Global Medical Lead in Medical Affairs at BioMarin where he managed the Lysosomal Storage disease and PKU franchises. Dr. Imperiale also held the Vice President of Clinical Research position at Talon Therapeutics (Hana Biosciences), where he successfully developed Marquibo[®] for adult Acute Lymphocytic Leukemia (ALL).

Dr. Imperiale began his career in drug development at Boehringer-Ingelheim, where he initiated the International Medical Affairs division for Virology. In recognition for his achievements, he received the Medical Marketing Award. He received a Doctor of Medicine, with an Academic Distinction in Medicine, from Hahnemann University School of Medicine

For personal use only

and a Bachelor of Arts degree from Villanova University.

Dr. Imperiale will also head up Paradigm's MPS IV clinical program with his significant experience in Lysosomal Storage Diseases.

Mr. Paul Rennie, Paradigm's Chief Executive Officer said:

"I am thrilled to welcome both Jeannie and Michael to the Paradigm team. It is a very exciting time for Paradigm and to add two highly experienced staff members whose diverse skills will complement the current Paradigm team is very pleasing. Both Jeannie and Michael will play integral roles as Paradigm continues to prepare for multiple clinical trials, 2 x Phase 3 clinical trials in Osteoarthritis, one Phase 2 in MPS-I and one Phase 3 in MPS-VI. Paradigm has an ambitious clinical development program and having two highly experienced executives join our team, at this time, further prepares us for timely execution of these programs".

In welcoming Jeannie to the COO role, I would like to pay tribute to Dr Claire Kaufman, Paradigm's inaugural COO: "Claire's leadership and experience was pivotal in both our early start-up phase and later as the clinical program developed. We wish her well in her future endeavours".

Authorised for release by Paul Rennie, Managing Director & CEO

To learn more please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com

For personal use only